CVac boosts OS in second-remission ovarian cancer
03 June, 2014 by Dylan Bushell-EmblingData from a phase II trial of Prima BioMed's (ASX:PRR) CVac show that the treatment has had a positive effect on overall survival in ovarian cancer patients in second-line remission.
Supporting Indigenous health
03 June, 2014A $10 million philanthropic gift will be used to establish a Poche Centre for Indigenous Health at the University of Melbourne.
Virax completes purchase of Pathway Oncology
02 June, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has closed the deal to acquire Pathway Oncology, and with it an exclusive licence to a first-in-class cancer therapeutic candidate.
Patient responds well to Patrys's PAT-SM6
29 May, 2014 by Dylan Bushell-EmblingA patient with relapsed multiple myeloma responded well to a combination of Patrys's (ASX:PAB) PAT-SM6 and a proteosome inhibitor, which bodes well for an upcoming trial.
Sienna reagent and cancer biomarker registered with FDA
29 May, 2014The US FDA has registered the lead product of Melbourne-based biotech company Sienna Cancer Diagnostics - the antibody SCD-A7.
Novogen to test SBPs in prostate cancer
27 May, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a number of super-benzopyran (SBP) compounds with a potent effect against prostate cancer cells in vitro, and aims to trial the lead candidate in 2015.
Prima's US patent for CVac allowed
26 May, 2014 by Dylan Bushell-EmblingThe US patent office has granted Prima BioMed a Notice of Allowance covering a patent application protecting cancer treatment candidate CVac.
IST raising $5m for cancer trial, ASX listing
21 May, 2014 by Dylan Bushell-EmblingImmune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter.
No link between vaccinations and autism
21 May, 2014A comprehensive systematic review of childhood vaccinations has found no evidence of a link to the development of autism or autism spectrum disorders.
Budget delivers a mixed bag for science
16 May, 2014 by Susan WilliamsonThe federal government's first Budget delivers a mixed outcome for science, research and innovation.
Scientific congress for the therapeutics sector
16 May, 2014If you are a professional working in the therapeutics sector, don't miss the 2014 ARCS Scientific Congress to be held in Sydney at the beginning of June.
Virax names new managing director
15 May, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has announced that former Arana Therapeutics executive Dr Rob Crombie will join the company as managing director in mid-June.
Prana adds movement disorder expert to board
14 May, 2014 by Dylan Bushell-EmblingNeurodegenerative disease expert professor Ira Shoulson has joined the Prana Biotechnology (ASX:PBT) board to help the company develop PBT2 as a treatment for Huntington disease.
Prima gets FDA fast-track status for CVac
09 May, 2014 by Dylan Bushell-EmblingShares in Prima BioMed grew 30% after the company revealed it has won fast-track designation in the US for CVac in platinum-sensitive epithelial ovarian cancer in second remission.
Awards for research excellence open
09 May, 2014Nominations are open for the annual Research Australia Awards and the 2014 GlaxoSmithKline Award for Research Excellence.
